A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial

INTRODUCTION: Alzheimer’s disease (AD), a progressive neurodegenerative disease, is the main cause of dementia and one of the leading causes of death for elderly people in the USA. Lecanemab is a humanized IgG1 monoclonal antibody targeting amyloid protofibrils for the treatment of early AD [i.e., m...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahami Monfared, Amir Abbas, Ye, Weicheng, Sardesai, Aditya, Folse, Henri, Chavan, Ameya, Aruffo, Elena, Zhang, Quanwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195966/
https://www.ncbi.nlm.nih.gov/pubmed/37009976
http://dx.doi.org/10.1007/s40120-023-00473-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195966/
https://www.ncbi.nlm.nih.gov/pubmed/37009976
http://dx.doi.org/10.1007/s40120-023-00473-w

Ejemplares similares